ADMA Biologics (ADMA) Q1 2025 earnings summary

Executive summary

• Achieved 40% year-over-year revenue growth to $114.8M in Q1 2025, driven by strong ASCENIV sales, vertically integrated U.S.-based supply chain, and expanded market acceptance.

• FDA approval of a novel yield enhancement process enables 20% more IG output from the same plasma, supporting future revenue and margin expansion.

• Net income rose to $26.9M from $17.8M in Q1 2024, with gross margin improving to 53.2% (54.7% adjusted) from 47.8% year-over-year.

• Announced a $500M share repurchase program (~8% of market cap) and reduced cost of debt through debt reorganization.

• Raised 2025 and 2026 financial guidance, reflecting confidence in continued revenue and margin expansion, especially as ASCENIV becomes a larger share of the revenue mix.

Financial highlights

• Q1 2025 total revenue was $114.8M, up $32.9M (40%) year-over-year; adjusted for voluntary product withdrawals, revenue would have been $118.6M (45% growth).

• Gross profit reached $61.1M, with gross margin improving to 53.2% (or 54.7% adjusted), up from 47.8% in Q1 2024.

• Adjusted EBITDA grew 81% year-over-year to $47.9M; adjusted net income rose 87% to $33.3M.

• GAAP net income was $26.9M, up from $17.8M in Q1 2024.

• Cash and receivables totaled $171M at quarter-end, supporting ongoing growth and capital initiatives.

Outlook and guidance

• 2025 revenue guidance raised to $500M+; adjusted EBITDA to at least $235M; adjusted net income to $175M+.

• 2026 guidance increased to $625M+ revenue, $340M+ adjusted EBITDA, and $245M+ adjusted net income.

• Long-term annual revenue target prior to 2030 raised to $1.1B+.

• Guidance for 2025 excludes potential upside from yield enhancement process until inventory transition is complete; included in 2026 guidance.

• No need for additional capital anticipated; current cash, receivables, and projected cash flow expected to fund operations beyond 2025.